Cancer immunotherapy based on blockade of the PD-1/PD-L1 interaction by immune checkpoint inhibitors (ICIs) has been established as one of the main therapeutic strategies for cancer, particularly non-small-cell lung cancer (NSCLC) [2–5]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.